CD8A and neoplasm: documented the emergence of significant tumor immune mobilization mediated by CD4 and CD8+ T lymphocytes following the initiation of Pembrolizumab in their patient, resulting in near-complete response of their MPM, while maintaining a negative PD-L1 status (17).